Raymond James initiated coverage of Tvardi Therapeutics (TVRD) with an Outperform rating and $62 price target The company is developing TTI-101 in idiopathic pulmonary fibrosis, an indication where blockbuster antifibrotics “have left plenty of room for improvement,” the analyst tells investors in a research note. The firm believes TTI-101’s clinical efficacy and safety profile so far provides strong therapeutic evidence.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVRD:
- Tvardi Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Coinbase, Datadog, Tvardi, CF, Conagra: Trending by Analysts
- Tvardi Therapeutics initiated with an Overweight at Piper Sandler
- Tvardi Therapeutics Updates Corporate Presentation on Therapies
- Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks